Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Licensing Agreements
BioVeris completes new vaccine license
January 24th, 2007
BioVeris Corp. (BIOV) announced that it has entered into a Technology License Agreement with Baxter Healthcare Corp. BioVeris received nonexclusive, worldwide patent rights and know-how to use Neisseria meningitidis group C vaccine as a component in new vaccine candidates for the prevention of meningitis and sepsis. The new combination vaccine candidates would consist of the Neisseria meningitidis group C components and additional vaccine candidates to protect against other disease causing organisms. These new combination vaccines are expected to have the advantage of reducing the number of injections that a child would receive during a single office visit. ...
Source: Vaccine Weekly (2007-01-24)
|
